Search

Displaying results 2111 - 2120 of 4247 in total
  1. Drug

    Levomenol

    go.drugbank.com/drugs/DB13153
    Approved

    Bisabolol, or more formally α-(−)-bisabolol or also known as levomenol, (-)-alpha-Bisabolol is found in fats and oils. (-)-alpha-Bisabolol is isolated from essential oil of Matricaria chamomilla (German

  2. Drug

    Dichloralphenazone

    go.drugbank.com/drugs/DB01495
    ApprovedIllicit

    It is a US Schedule IV drug and its clinical use is limited.

  3. Drug

    Penicillamine

    go.drugbank.com/drugs/DB00859
    ApprovedInvestigational

    The pharmaceutical form is D-penicillamine, as L-penicillamine is toxic (it inhibits the action of pyridoxine).

  4. Drug

    Lanolin alcohols

    go.drugbank.com/drugs/DB14181
    Approved

    It is administered as an ointment base with topical insulin and has shown to be antagonistic to wound healing. It is commonly used in allergenic testing.

  5. Drug

    Thrombomodulin Alfa

    go.drugbank.com/drugs/DB05777
    Approved

    It is a human protein with both thrombin inhibiting and protein C stimulating activities, for the potential treatment of thromboembolism and blood clotting disorders, such as disseminated intravascular

  6. Drug

    Norgestrel

    go.drugbank.com/drugs/DB09389
    Approved

    Norgestrel is synthetic steroidal progestin that is used in combination with ethinyl estradiol for oral contraception. Norgestrel is composed of a racemic mixture of two stereoisomers, dextronorgestrel and levonorgestrel. However, only t...

  7. Drug

    P-113D

    go.drugbank.com/drugs/DB04987
    Experimental

    It is being pursued as a potential treatment for cystic fibrosis by Demegen, Inc.

  8. Drug

    CNS-5161

    go.drugbank.com/drugs/DB05824
    Experimental

    CNS 5161 is a blocker of the NMDA ion channel and has completed Phase IIa proof of concept clinical trials as a novel compound for the treatment of neuropathic pain.

  9. Drug

    Cannabidivarin

    go.drugbank.com/drugs/DB14050
    Investigational

    CBD and CBDV have been shown to dose-dependently activate and then desensitize TRPV1 as well as TRPV2 and TRPA1 channels [A31560, A33334, A32976]. … Cannabidivarin is being actively developed by GW Pharmaceuticals as the experimental compound GWP42006 as it has "shown the ability to treat seizures in pre-clinical models of epilepsy with significantly

  10. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).